News | December 23, 2023
Lupin Atlantis Holdings to acquire accretive established products in Europe and Canada from Sanofi
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Subscribe To Our Newsletter & Stay Updated
